by Greg Kuehn | Mar 20, 2020 | Research News
Research will examine prevalent gut microbial markers present in colorectal cancer CARLSBAD, Calif., June 2, 2020 /PRNewswire/ — Prescient Metabiomics, a subsidiary of Prescient Medicine Holdings, Inc., announced today a research collaboration with the Harvard Chan...
by Greg Kuehn | Dec 17, 2019 | Research News
CARLSBAD, Calif., Dec. 17, 2019 /PRNewswire/ — Prescient Metabiomics, a subsidiary of Prescient Medicine Holdings, Inc., and CoreBiome, a wholly owned subsidiary of OraSure Technologies, Inc., announced today a collaboration to develop a new test called LifeKit®...
by Greg Kuehn | Apr 15, 2018 | Research News
Patrick M. Gillevet, Ezzat Dadkhah, Masoumeh Sikaroodi, Swati Dalmet, Louis Y. Korman, Robert Hardi, Jeffrey H. Baybick, David K. Hanzel, Greg Kuehn, Thomas Kuehn Background: Alterations in the colonic microbiota are likely to play a role in colonic...
by Greg Kuehn | Jun 19, 2017 | Press Releases, Research News
Manassas, VA, June 19, 2017 – Metabiomics is proud to announce the completion of one of the largest case-controlled studies on the colorectal polyp microbiome. Titled “Metabiomics Neoplasia Clinical Research Study”, also referred to as MB-01 by Metabiomics, the study...
by Greg Kuehn | Mar 17, 2014 | Research News
Chevy Chase, MD, March 17, 2014 Metabiomics is pleased to announce the launch of a new IRB approved microbiome clinical research study titled “Metabiomics Neoplasia Clinical Research Study”, also referred to as MB-01. The ~200 patient study will be conducted in...
by Greg Kuehn | Dec 10, 2013 | Research News
POTOMAC FALLS, VA, December 10, 2013 Metabiomics is pioneering the development of molecular diagnostic tests for colorectal cancer, inflammatory bowel disease, and other gastrointestinal cancers and autoimmune diseases built on an exclusive worldwide license from...
